Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Hydroxychloroquine (HCQ) showed no clear difference in death due to any cause compared with standard care or placebo (high certainty).
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with placebo (moderate certainty).
Hydroxychloroquine (HCQ) showed no clear difference in negative PCR for SARS‐CoV‐2 on respiratory samples at day 14 from… compared with standard care or placebo (low certainty).
Hydroxychloroquine (HCQ) showed no clear difference in progression to mechanical ventilation compared with standard care or placebo (moderate certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes time to clinical improvement compared with standard care or placebo (very low certainty).
Hydroxychloroquine (HCQ) probably leads to higher participants with any adverse events compared with standard care or placebo (moderate certainty).
Hydroxychloroquine (HCQ) showed no clear difference in participants with serious adverse events compared with standard care or placebo (low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes participants with prolongation of QT‐interval on ECG compared with standard care or placebo (very low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes development of confirmed COVID‐19 at 14 days from enrolment compared with placebo (very low certainty).
It is very uncertain whether hydroxychloroquine (HCQ) changes hospitalized due to COVID‐19c compared with placebo (very low certainty).
It is very uncertain whether siponimod changes number of participants with relapses at 6 months compared with placebo (very low certainty).
Siponimod may leads to lower participants with disability worsening at 6 months compared with placebo (low certainty).
Siponimod showed no clear difference in number of participants who withdrew due to AEs at 6 months compared with placebo (low certainty).
Siponimod may leads to lower annualised relapse rate compared with placebo (low certainty).
It is very uncertain whether siponimod changes mean number of gadolinium‐enhancing lesions on T1‐weighted brain MRI… compared with placebo (very low certainty).
Siponimod may leads to lower mean number of new lesions or enlarged pre‐existing lesions on… compared with placebo (low certainty).
Siponimod showed no clear difference in number of participants with at least one SAE at 6 months compared with placebo (low certainty).
DPP4i showed no clear difference in cardiovascular mortality compared with placebo (high certainty).
GLP‐1RA leads to lower cardiovascular mortality compared with placebo (high certainty).